Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment

American Journal of Psychiatry

Volumn 158, Issue 2, 2001, Pages 176-184

  Harvey, P D ^a   Keefe, R S E ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; HALOPERIDOL; NEUROLEPTIC AGENT;

ALERTNESS; CLINICAL RESEARCH; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MEMORY; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; VISUOMOTOR COORDINATION;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; COGNITION; COGNITION DISORDERS; HUMANS; NEUROPSYCHOLOGICAL TESTS; OUTCOME ASSESSMENT (HEALTH CARE); SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0035140610     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.158.2.176     Document Type: Review

References (61)

1. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia
2. Extrapyramidal symptoms in patients treated with risperidone
3. Effects of risperidone in tardive dyskinesia: An analysis of the Canadian Multicenter Risperidone study
4. Clinical effects of clozapine in chronic schizophrenia: Response to treatment and predictors of outcome
5. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine
6. Risperidone in the treatment of schizophrenia
7. Olanzapine versus haloperidol: Acute phase results of the North American Double-Blind Olanzapine Trial
8. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance
9. Effects of clozapine on cognitive function in schizophrenia
10. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia
11. Improvement in cognitive function and psychotic symptoms in treatment-refractory schizophrenic patients
12. The comparative efficacy and long-term effect of clozapine on neuropsychological test performance
13. Effects of clozapine, fluphenazine, and placebo on reaction time measures of attention and sensory dominance in schizophrenia
14. Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: A pilot study
15. Long-term impact of clozapine and psychosocial treatment of psychiatric symptoms and psychosocial functioning
16. The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients
17. The effects of clozapine on cognition in treatment-resistant schizophrenic patients
18. Relationships between changes in symptom ratings, neuropsychological test performance and quality of life in schizophrenic patients treated with clozapine
19. Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: Results from a double-blind study
20. Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenics: A prospective study
21. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia
22. Risperidone, negative symptoms, and cognitive deficits in schizophrenia: An open study
23. The effect of risperidone on cognition in patients with schizophrenia
24. Does risperidone improve verbal working memory in treatment-resistant schizophrenia?
25. Verbal learning in schizophrenia: Effects of novel antipsychotic medication
26. Risperidone vs haloperidol on re-action time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients
27. Risperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: Preliminary findings
28. The effects of risperidone vs haloperidol on cognitive functioning in treatment-resistant schizophrenia: The Trail Making Test
29. Novel neuroleptics improve attentional functioning in schizophrenic patients
30. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol
31. Attentional improvement following quetiapine fumarate treatment in schizophrenia
32. What are the functional consequences of neurocognitive deficits in schizophrenia?
33. Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: A comparison across treatment sites
34. New antipsychotic medications: What advantages do they offer?
35. Recent advances in the pharmacotherapy of schizophrenia
36. The pharmacoeconomics of clozapine: A review
37. Effects of limiting Medicaid drug-reimbursements benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia
38. Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy: A retrospective analysis using the Saskatchewan Health linkable databases
39. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol
40. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia
41. Clozapine's effectiveness for patients in state hospitals: Results from a randomized trial
42. The cost of cognitive impairment in schizophrenia
43. Cognitive impairment as a target for pharmacological treatment in schizophrenia
44. The effect of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis
45. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine
46. Cognitive dysfunction in schizophrenia: Comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs
47. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients
48. Clozapine treatment of outpatients with schizophrenia: Outcome and long-term response patterns
49. Efficacy and safety of risperidone in the long-term treatmerit of patients with schizophrenia
50. Treatment of acute schizophrenia with ultra-high-dose fluphenazine: A failure at shortening time on a crisis-intervention unit
51. Controlled dose comparison of haloperidol in newly admitted schizophrenic patients
52. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia
53. Neuropsychological performance in chronic schizophrenia in response to neuroleptic dose reduction
54. Severity of symptoms in chronically institutionalized geriatric patients
55. Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the "right stuff?"
56. Relation of sample size to the stability of component patterns
57. Sample size calculations in studies of test accuracy
58. Small sample longitudinal clinical trials with missing data: A comparison of analytic methods
59. Neuropsychological deficits in schizophrenics: Relationship to age, chronicity, and dementia
60. Cognitive functioning and positive and negative symptoms in schizophrenia